{"id":"W2264781158","doi":"10.1200/jco.2006.24.18_suppl.13054","title":"A phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM-h-R3 (nimotuzumab) in patients with advanced solid tumors","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nimotuzumab; Tolerability; Internal medicine; Toxicity; Gastroenterology; Phases of clinical research; Cancer; Mucositis; Oncology; Epidermal growth factor receptor; Pharmacology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001132162,0.001252759,0.001572157,0.0003070023,0.0003226315,0.0006111407,0.0006959563,0.0007267614,0.001854384],"category_scores_gemma":[0.0005135515,0.0003576342,0.0008594151,0.0003303952,0.0006278214,0.0004187971,0.0002875641,0.001840278,0.0007045359],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007960526,"about_ca_system_score_gemma":0.001481538,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009839883,"about_ca_topic_score_gemma":0.001789949,"domain_scores_codex":[0.9997197,0.0001333881,0.00001246522,0.00005101093,0.00003119735,0.00005221186],"domain_scores_gemma":[0.9996062,0.00005838406,0.00005500788,0.00002927638,0.00002577587,0.0002254269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3953167,0.1265076,0.02032326,0.001775551,0.001799627,0.001635725,0.000834998,0.007979983,0.211611,0.0007163443,0.01097743,0.2205218],"study_design_scores_gemma":[0.4406089,0.5204809,0.02305948,0.00003578219,0.0004002265,0.0008378209,0.00005409843,0.002446572,0.006793767,0.0002519012,0.004998055,0.00003242055],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930588,0.001431637,0.0008314849,0.0002647227,0.00009325043,0.00208525,0.0006148738,0.00007556946,0.001544337],"genre_scores_gemma":[0.989029,0.001485919,0.002487712,0.0005696665,0.0001354687,0.002266722,0.00229755,0.00002875308,0.001699188],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001854384,"threshold_uncertainty_score":0.006203532,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04981963900224151,"score_gpt":0.4414129051185002,"score_spread":0.3915932661162587,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}